NCT Number: NCT02889458
Hong Kong Breast Cancer Study
Introduction: With population ageing and increasing Westernization breast cancer continues to be important health conditions among women in Hong Kong. Greater collaborative research efforts are needed to examine the questions about population screening for breast cancer, the aetiology of such lesions and outcomes of breast cancer during survivorship period. There is a lack of locally-relevant models for assessing breast cancer risk. Contribution of novel genetic factors to breast cancer, identification of the key and functional alleles in gene regions associated with risk of breast cancer as well as gene-environment interaction, requires further investigation in Chinese population. Prognostic research studies in the West may not be readily applicable to the Chinese population.
Objectives: We aim to investigate the aetiology and outcomes of breast cancer in local Chinese by using case-control and cohort study design in the health care setting in Hong Kong. We aim to examine potential risk factors/biomarkers (both traditional and novel), and to build infrastructure and biobank for breast cancer surveillance. We will follow up cases prospectively as a survivor cohort.
Methods: A hospital-based case-control study and a prospective survivor cohort study will be conducted. Consecutive incident breast cancer and DCIS cases (n=3,501) within a 36-month period in Hong Kong were recruited from public hospitals, private hospitals and private practices; and controls were selected by frequency-matching on factors such as age and hospital/clinic setting, whenever possible. Cases will be prospectively followed up over a 10-year period, and data collection will occur at baseline (within 24 weeks of diagnosis), 3, 5 and 10 years following baseline assessment. Biologic samples (including both blood, and tumour and normal breast tissue samples from the cases, and blood samples from the controls) will be collected for later genetic and molecular study including WGS, GWAS, gene-environment interaction and molecular functional studies. Depending on availability of pathology samples and resources, additional studies such as tissue microarray block production will be considered and performed in future. Data will be analysed by traditional regression, EWAS and genetic association methods, whenever relevant.
Public Health Implications: The repository of clinical, radiological and biological materials assembled through this case-control study will serve as a common, publicly accessible platform for subsequent functional analysis and scientific interrogation. The case-control findings would offer an improved understanding to the state of the science on aetiology of breast cancer in Chinese women. In the genomics analysis, potential refined classification of breast tumours may enhance our understanding, detection and follow-up of such lesions, as well as enable us to have more informed targeted and personalized treatment selection for our women population. The cohort study findings are important for developing an effective strategy for the improvement of overall survival and quality of life for the cancer survivors in Chinese population.
This study is active but is not currently recruiting participants.
Key information
Conditions
Age range
18 year and older
Sex eligibility
Female
Study type
Observational
Primary location
Baptist Hospital, Hong Kong
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Case Inclusion Criteria:
- Female
- aged 18 or above
- Chinese
- Usually residing in Hong Kong (Definition: Having stayed in HK for at least three months during the six months before the reference time-point)
- Able to speak Cantonese
- Newly diagnosed with breast cancer or DCIS in 24 weeks
Case Exclusion Criteria:
- Undergoing treatment for any non-breast cancer
Control Inclusion Criteria
- Female
- aged 18 or above
- Chinese
- Usually residing in Hong Kong
- Able to speak Cantonese
Control Exclusion Criteria
- History of any cancer
Treatment and study plan
Primary outcomes
-
probability of developing breast cancer
Time frame: 2 years
We will estimate individualized breast cancer probabilities based on information on relative risks and the baseline hazard rate in Hong Kong Chinese women population. Risk factors will include age, age at menarche, age at first birth, family history of breast cancer, prior breast benign disease diagnosis, menopausal status, dietary pattern. Structured interviews will be provided by our trained interviewers to collect these data by using our survey questionnaire.
Sponsors and collaborators
Lead sponsor
The University of Hong Kong
Other
Collaborators
- Food and Health Bureau, Hong Kong
Registry information
Official study title
Preventing Breast Cancer in Hong Kong Chinese Women Through Personalized Risk Stratification and Characterization: an Epidemiologic Modeling Study and the Development of a Biorepository of Cases and Controls
Important dates
- Study start
- 2016
- Primary completion
- 2022
- Study completion
- 2028
- First posted
- Sep 5, 2016
- Registry last updated
- May 23, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Intraoperative Radiation Therapy (IORT) in DCIS
NCT03216421
Adenocarcinoma, Breast Cancer
New York, United States
View Trial DetailsHISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery
NCT07527468
Adenocarcinoma, Breast Cancer
Sion, Valais, Switzerland
View Trial DetailsUltra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT06902311
Adenocarcinoma, Breast Cancer
Chapel Hill, North Carolina, United States
View Trial DetailsBreast Tumour Size Measurement by Field Cycling Imaging
NCT07492043
Adenocarcinoma, Breast Cancer
Aberdeen, United Kingdom
View Trial Details